Developing single-dose tafenoquine | World Malaria Day
Dr Isabelle Borghini, Senior Director of Product Development and Dr Stephan Duparc, Chief Medical Officer, discuss the newly approved treatment for Plasmodium vivax malaria in children, single-dose tafenoquine, which was developed in partnership with GSK.
Supporting African manufacturing | World Malaria Day
Pierre Hugo, MMV’s Senior Director of Market Dynamics and Global Access Partnerships talks about MMV’s cooperation with African partners to build capacity to develop antimalarials that achieve World Health Organization (WHO) pre-qualification standards for people living in Africa, where 90% of malaria cases take place today.
Driving SMC to protect kids from malaria | World Malaria Day
Dr Abena Poku-Awuku and Dr André-Marie Tchouatieu talk about seasonal malaria chemoprevention, an intervention approved by WHO in 2012 to protect children in sub-Saharan Africa during the malaria season.
Machine learning and AI in drug discovery | World Malaria Day
Dr Benoit Laleu, Associate Director of Drug Discovery, talks about how MMV and its collaborators are using machine learning and artificial intelligence to discover new compounds with a view to lead us towards malaria elimination.